Amgen has entered into an agreement with Celgene Corp., in connection with its previously announced merger with Bristol-Myers Squibb, to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash. Amgen believes that the acquisition is a strong strategic fit with its inflammation franchise offering a differentiated, oral therapy, along with Otezla’s sales growt...